[go: up one dir, main page]

WO2019088541A3 - Composition contenant un extrait de salvia miltiorrhiza pour la prévention, la réduction ou le traitement de l'obésité viscérale - Google Patents

Composition contenant un extrait de salvia miltiorrhiza pour la prévention, la réduction ou le traitement de l'obésité viscérale Download PDF

Info

Publication number
WO2019088541A3
WO2019088541A3 PCT/KR2018/012522 KR2018012522W WO2019088541A3 WO 2019088541 A3 WO2019088541 A3 WO 2019088541A3 KR 2018012522 W KR2018012522 W KR 2018012522W WO 2019088541 A3 WO2019088541 A3 WO 2019088541A3
Authority
WO
WIPO (PCT)
Prior art keywords
visceral fat
obesity
salvia miltiorrhiza
alleviation
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/012522
Other languages
English (en)
Korean (ko)
Other versions
WO2019088541A2 (fr
Inventor
윤주석
김누리
손정환
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huen Co ltd
Original Assignee
Huen Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180125449A external-priority patent/KR102005423B1/ko
Application filed by Huen Co ltd filed Critical Huen Co ltd
Priority to CN201880031146.9A priority Critical patent/CN110612111A/zh
Priority to JP2019565315A priority patent/JP2021501119A/ja
Priority to EP18873842.1A priority patent/EP3705127A4/fr
Priority to US16/615,148 priority patent/US20200171115A1/en
Publication of WO2019088541A2 publication Critical patent/WO2019088541A2/fr
Publication of WO2019088541A3 publication Critical patent/WO2019088541A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition pour la prévention, la réduction ou le traitement de l'obésité viscérale, comprenant un extrait de Salvia miltiorrhiza, qui présente une excellente activité en matière de réduction du tissu adipeux viscéral. La présente invention concerne une composition pour la prévention, la réduction ou le traitement de l'obésité viscérale, comprenant un extrait de Salvia miltiorrhiza dont on s'est aperçu qu'il présente une efficacité spécifique contre le tissu adipeux viscéral comme mesuré chez des modèles animaux de souris souffrant d'obésité en raison d'une baisse de la sécrétion de leptine et chez des souris souffrant d'une obésité induite par un régime riche en matières grasses. La présente invention concerne une composition comprenant un extrait de Salvia miltiorrhiza pour la prévention, la réduction ou le traitement de l'obésité viscérale, l'activité inhibitrice de l'extrait de Salvia miltiorrhiza contre l'obésité viscérale étant utilisée pour entraîner un effet de réduction du tissu adipeux viscéral en supprimant la génération de triglycérides TG in vivo dans les tissus hépatiques et le sang et en réduisant l'expression des ALT, LDH, BUN, FFA ou Hb A1C sanguins, comme observé à l'IRM et par spectroscopie de l'hydrogène.
PCT/KR2018/012522 2017-10-31 2018-10-23 Composition contenant un extrait de salvia miltiorrhiza pour la prévention, la réduction ou le traitement de l'obésité viscérale Ceased WO2019088541A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201880031146.9A CN110612111A (zh) 2017-10-31 2018-10-23 含有丹参提取物的预防、改善或治疗内脏脂肪型肥胖的组合物
JP2019565315A JP2021501119A (ja) 2017-10-31 2018-10-23 丹参抽出物を含む内臓脂肪型肥満予防、改善又は治療組成物
EP18873842.1A EP3705127A4 (fr) 2017-10-31 2018-10-23 Composition contenant un extrait desalvia miltiorrhiza
US16/615,148 US20200171115A1 (en) 2017-10-31 2018-10-23 Composition for preventing or treating visceral fat obesity containing extract of salvia miltiorrhiza radix

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2017-0143582 2017-10-31
KR20170143582 2017-10-31
KR1020180125449A KR102005423B1 (ko) 2017-10-31 2018-10-19 단삼 추출물을 함유하는 내장지방형 비만 예방, 개선 또는 치료 조성물
KR10-2018-0125449 2018-10-19

Publications (2)

Publication Number Publication Date
WO2019088541A2 WO2019088541A2 (fr) 2019-05-09
WO2019088541A3 true WO2019088541A3 (fr) 2019-06-27

Family

ID=66332090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/012522 Ceased WO2019088541A2 (fr) 2017-10-31 2018-10-23 Composition contenant un extrait de salvia miltiorrhiza pour la prévention, la réduction ou le traitement de l'obésité viscérale

Country Status (1)

Country Link
WO (1) WO2019088541A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100818586B1 (ko) * 2003-12-30 2008-04-01 주식회사 케이티앤지 대사활성을 촉진시키는 탄시논 유도체를 유효성분으로함유하는 비만 및 대사증후군 치료제
KR100854442B1 (ko) * 2006-07-05 2008-08-26 박영준 하엽 추출물 또는 생약복합제 추출물을 함유하는 고지혈증 및 동맥경화증의 예방 및 치료용 조성물
KR101109620B1 (ko) * 2009-04-15 2012-01-31 주식회사 바이오랜드 단삼소납을 함유하는 피부미백 화장료 조성물
KR101468449B1 (ko) * 2007-04-26 2014-12-04 주식회사 케이티앤지생명과학 신규한 페난스렌퀴논계 화합물 및 이를 포함하는대사증후군 질환의 치료 또는 예방용 약제 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100818586B1 (ko) * 2003-12-30 2008-04-01 주식회사 케이티앤지 대사활성을 촉진시키는 탄시논 유도체를 유효성분으로함유하는 비만 및 대사증후군 치료제
KR100854442B1 (ko) * 2006-07-05 2008-08-26 박영준 하엽 추출물 또는 생약복합제 추출물을 함유하는 고지혈증 및 동맥경화증의 예방 및 치료용 조성물
KR101468449B1 (ko) * 2007-04-26 2014-12-04 주식회사 케이티앤지생명과학 신규한 페난스렌퀴논계 화합물 및 이를 포함하는대사증후군 질환의 치료 또는 예방용 약제 조성물
KR101109620B1 (ko) * 2009-04-15 2012-01-31 주식회사 바이오랜드 단삼소납을 함유하는 피부미백 화장료 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHOI, SEON UK ET AL.: "The Effects of Salvia miltiorrhiza on High Fat Diet-induced Obese Diabetic Mouse Model", JOURNAL OF KOREAN ORIENTAL INTERNAL MEDICINE, vol. 33, no. 4, 2012, pages 429 - 437, XP053029886 *
See also references of EP3705127A4 *

Also Published As

Publication number Publication date
WO2019088541A2 (fr) 2019-05-09

Similar Documents

Publication Publication Date Title
MX2020010603A (es) Extracto de cáñamo para tratamiento de dolor en animales.
MX2025006821A (es) Extractos botanicos y bacterianos que muestran actividad similar al retinol
Kim Role of ERK/MAPK signalling pathway in anti-inflammatory effects of Ecklonia cava in activated human mast cell line-1 cells
BRPI0819690B8 (pt) uso de uma composição compreendendo cisteamina ou cistamina, ou um sal farmaceuticamente aceitável das mesmas
WO2011102684A3 (fr) Composition contenant des extraits de placenta
BR112021010865A2 (pt) Composição compreendendo um pepitídeo inibidor contra a sinalização de fas e uso dos mesmo para prevenção ou tratamento da obesidade, fígado gorduroso ou esteato-hepatite
EP2558102A4 (fr) Interaction synergique d'au moins un constituant de vitamine e et d'inhibiteurs de tyrosinase pour applications dermatologiques
WO2011064401A3 (fr) Extrait de graines de vigna unguiculata et compositions le comprenant
WO2015109299A3 (fr) Extraits de bambou, compositions et utilisations de ceux-ci
MX2018000262A (es) Usos terapeuticos de formulaciones de berberina.
ATE522224T1 (de) Medizinisches kräuterextrakt mit wirkung gegen adipositas
WO2011090271A3 (fr) Composition contenant de l'extrait de pépins de litchi pour prévenir ou traiter la stéatose hépatique ou l'obésité
Higa et al. Phyllostachys edulis compounds inhibit palmitic acid-induced monocyte chemoattractant protein 1 (MCP-1) production
WO2019088541A3 (fr) Composition contenant un extrait de salvia miltiorrhiza pour la prévention, la réduction ou le traitement de l'obésité viscérale
WO2016048005A3 (fr) Nouveau dérivé de pipéridine pentadiénoyl et son utilisation
WO2018230931A3 (fr) Composition pour prévenir et traiter les maladies métaboliques
WO2010140855A3 (fr) Composition pharmaceutique pour composition alimentaire fonctionnelle permettant de traiter, prévenir ou soulager l'hypertrophie cardiaque, qui renferme de l'extrait de framboise
WO2010114215A3 (fr) Composition de prevention ou de traitement de l'obesite, de la dyslipidemie, de la steatose hepatique ou du syndrome de resistance a l'insuline, contenant du camphre comme principe actif
JP2016040314A5 (ja) 血圧降下作用及び心拍数低下作用を有する組成物および機能性食品、並びにヤナギタデ抽出物の製造方法
WO2012108676A3 (fr) Nouveau composé à activités de blanchiment de la peau, anti-oxydante pour la peau et ppar et utilisation médicale correspondante
MX2020000999A (es) Agonistas del receptor de prostacyclin para reducir la grasa corporal.
Joukar et al. Research Article Assessment of Safety and Therapeutic Efficacy of Rosa damascena L. and Quercus infectoria on Cardiovascular Performance of Normal and Hyperlipidemic Rabbits: Physiologically Based Approach
EP4366753B8 (fr) Utilisation d'un extrait végétal de salvia haenkei comme agent actif dans le traitement de maladies cardiaques
EP4243840A4 (fr) Méthodes et compositions thérapeutiques utilisant une fraction vasculaire stromale dérivée de tissu adipeux
JP2016513647A5 (fr)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18873842

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2019565315

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018873842

Country of ref document: EP

Effective date: 20200602